Therapeutic area intelligence for PARP Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

AstraZeneca →

Assets

Lynparza →

Olaparib →

Recent signals(2)

ClinicalJuly 26, 2026

AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea

AstraZeneca is conducting a post-marketing surveillance study to evaluate the safety and effectiveness of Lynparza in real-world settings in South Korea.

ClinicalJune 24, 2026

Olaparib Investigated as Neoadjuvant Treatment in Ovarian Cancer Study

A study is underway to evaluate olaparib as a neoadjuvant treatment for patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.